文献速递肝病

经颈静脉肝内门体分流术后氨水平可识别肝性脑病高危患者

Ammonia Levels After Transjugular Intrahepatic Portosystemic Shunt Insertion Identify Patients at High Risk of Hepatic Encephalopathy.
PubMed 文献 · Clin Gastroenterol Hepatol · 2025-05-10

本文为针对经颈静脉肝内门体分流术(TIPS)后肝性脑病(HE)的评论性文章,指出HE是肝硬化患者TIPS术后最常见且相关的并发症,鉴于乳果糖或利福昔明可用于预防性治疗,识别TIPS术后HE极高危患者具有吸引力;目前已确立的危险因素如较高MELD评分或肌少症在个体患者层面不够可靠,TIPS术前氨水平单独不足以识别高危患者,作者假设TIPS术后最初几天内测量的氨水平可能识别HE高危患者。

要点

  • HE是肝硬化患者TIPS术后最常见且相关的并发症。
  • 乳果糖或利福昔明可用于预防性治疗,识别极高危患者有吸引力。
  • 作者假设TIPS术后最初几天内氨水平可识别HE高危患者。

核心结论

  • 作者假设TIPS术后最初几天内测量的氨水平可能识别HE高危患者。

研究设计与样本

  • 本文为针对TIPS术后HE危险因素的评论性文章,原文未报告研究设计与样本量。

主要发现

  • HE是肝硬化患者TIPS术后最常见且相关的并发症。
  • 已确立的危险因素如较高MELD评分或肌少症在个体患者层面不够可靠。
  • TIPS术前单独测量的氨水平不足以识别高危患者。

关键数值与推荐

  • 原文未报告具体数值或推荐条款。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hepatic encephalopathy (HE) remains the most frequent and relevant complications after the insertion of a transjugular intrahepatic portosystemic shunt (TIPS) in patients with liver cirrhosis.1 Given that prophylactic treatment is potentially available in the form of lactulose or rifaximin, it would be appealing to identify a group of patients at very high risk for post-TIPS HE in whom primary prophylaxis might be justified. Currently, established risk factors, such as a higher Model for End-stage Liver Disease (MELD) score or sarcopenia, are not very reliable at an individual patient level to establish personalized treatment strategies.1 Ammonia is the key metabolite involved in the pathophysiology of HE.2 However, ammonia levels measured before TIPS insertion alone are not useful in identifying high-risk patients. We hypothesized that ammonia levels measured within the first days after TIPS might identify patients at high risk of HE.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Labenz C, Schmidtke L, Pitton MB, et al. Ammonia Levels After Transjugular Intrahepatic Portosystemic Shunt Insertion Identify Patients at High Risk of Hepatic Encephalopathy. Clin Gastroenterol Hepatol. 2025. PMID: 40354918. doi:10.1016/j.cgh.2025.03.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。